- Q4 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 07, 2024€0.98 (-0.51%)Earnings
- Q3 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 09, 2023€1.01 (-3.81%)Earnings
- Q2 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 10, 2023€1.27Earnings
- Q1 2023 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 11, 2023€1.31Earnings
- Q4 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 09, 2023€1.34 (+3.68%)Earnings
- Q3 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 10, 2022€1.26 (+5.29%)Earnings
- Q2 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 11, 2022€1.5 (+4.50%)Earnings
- Q1 2022 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 12, 2022€1.17 (-0.21%)Earnings
- Lineage Cell Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 27, 2022
- Lineage Cell Therapeutics Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 20, 2022
- Q4 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 10, 2022€1.21 (+0.83%)Earnings
- Lineage Cell Therapeutics Inc To Discuss Worldwide OpRegen Collaboration Call TranscriptDec 20, 2021
- Q3 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 10, 2021€2.1 (-1.87%)Earnings
- Lineage Cell Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas (Virtual) TranscriptOct 18, 2021
- Q2 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 12, 2021€2.24 (+2.75%)Earnings
- Lineage Cell Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Lineage Cell Therapeutics Inc Webinar Featuring External Therapeutic Area Experts TranscriptJun 10, 2021
- Q1 2021 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 13, 2021€1.92 (-1.03%)Earnings
- Q4 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 11, 2021€1.84 (-0.54%)Earnings
- Lineage Cell Therapeutics Inc Corporate Analyst Meeting TranscriptFeb 22, 2021
- Lineage Cell Therapeutics, Inc. - Special Call TranscriptNov 17, 2020
- Q3 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 04, 2020€1.03 (+10.75%)Earnings
- Q2 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptAug 06, 2020€0.82 (+13.89%)Earnings
- Lineage Cell Therapeutics, Inc. - Special Call TranscriptJun 08, 2020
- Lineage Cell Therapeutics, Inc. - Special Call TranscriptMay 11, 2020
- Q1 2020 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 07, 2020€0.91 (-3.19%)Earnings
- Q4 2019 Lineage Cell Therapeutics Inc Earnings Call TranscriptMar 12, 2020€0.66 (-7.04%)Earnings
- Lineage Cell Therapeutics Inc at Solebury Trout KOL Day TranscriptNov 15, 2019
- Q3 2019 Lineage Cell Therapeutics Inc Earnings Call TranscriptNov 12, 2019€0.65 (-10.96%)Earnings
- Q2 2019 BioTime Inc Earnings Call TranscriptAug 08, 2019€0.85 (-1.16%)Earnings
- Q1 2019 BioTime Inc Earnings Call TranscriptMay 09, 2019€1.07Earnings
- Q4 2018 BioTime Inc Earnings Call TranscriptMar 14, 2019€1.42 (+2.16%)Earnings
Lineage Cell Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas (Virtual) Transcript
Hi. So we are welcoming you back to our Fall 2021 Best Idea series. This is the third chapter. My name is Mayank Mamtani. I'm a Senior Biotech Analyst representing the broader healthcare research efforts in trying to bring forward [health] growth ideas within the smid-cap space. This particular one focused within cell therapy. The name of the company is Lineage Cell Therapeutics, ticker LCTX, where I'm pleased to have with me members of the management team: Brian Culley, CEO; Kevin Cook, CFO; Gary Hogge, SVP, Clinical and Medical Affairs; and also very fortunate to be joined by Dr. Jordi Monés, a prominent KOL in the ophthalmology clinical development space. But his particular research is in macular and retinal degeneration. He currently serves as the director in Institut de la Mà cula and a principal investigator with the Barcelona Macula Foundation: Research for Vision.
Thank you, everyone, for joining us. Before we get started, need to make a quick set of disclosures. In the normal course of business, B. Riley Securities seeks to perform
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)